Injection Wegovy: The Weekly Shot at the 2.4 mg Dose

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

From the PlexusDx Education Hub, an evidence-first guide to GLP-1 medications, weight-management options, and their genetic backdrop.

Wegovy is the weight-management face of semaglutide, dosed higher than its diabetes-labeled sibling, and the "Wegovy injection" search usually asks whether it comes any other way. As of April 2026 it does not. Here is the format reality, how injection and oral delivery differ, the dose path to 2.4 mg, cost, and the genetics underneath.

Why Wegovy only comes as a weekly shot

Wegovy (semaglutide 2.4 mg) is available only as a once-weekly subcutaneous injection as of April 2026 — there is no oral Wegovy product. PlexusDx offers Semaglutide Injection and Semaglutide Oral as separate protocols under its Weight Management Protocols.

Wegovy versus the oral semaglutide tablet

The oral formulation of semaglutide is Rybelsus, also Novo Nordisk, and it is marketed for type 2 diabetes, not chronic weight management. So while an oral semaglutide exists, it is not a substitute for Wegovy — the indication and dosing differ, and Rybelsus is not the weight-management product.

The mechanics of a weekly injection versus a daily pill

Route drives the practical experience.

Predictable absorption from the pen

Injectable GLP-1 receptor agonists deliver predictable bioavailability and are typically dosed once weekly (liraglutide, once daily). The medication reaches the bloodstream reliably without surviving digestion first.

The fasting rules a tablet imposes

Oral GLP-1 receptor agonists must survive gastric digestion, so Rybelsus uses an absorption enhancer (SNAC) and requires strict fasting administration. Adherence then depends on preference, injection tolerance, timing needs, and lifestyle. Head-to-head efficacy data between oral and injectable semaglutide in chronic weight management is limited, and oral semaglutide is labeled for type 2 diabetes.

The 2.4 mg destination and how you reach it

Injectable semaglutide is titrated per label from 0.25 mg weekly through higher doses, with Wegovy going up to 2.4 mg and Ozempic up to 2 mg. Injectable tirzepatide runs from 2.5 mg weekly up to 15 mg, and Rybelsus starts at 3 mg daily and titrates to 7 or 14 mg. These figures never replace your prescriber's directions.

What each format means for your wallet

Oral and injectable formats are priced separately, carry different insurance coverage rules, and may qualify differently for manufacturer savings programs. The PlexusDx Weight Management Protocols publish per-protocol pricing on each relevant product page.

Reading your genetic baseline first

Before any GLP-1 pathway protocol, the Precision Peptide Genetic Test reads 14 pathways, 49 peptides, 150+ genetic insights — including variants in FTO, GLP1R, and MC4R that shape appetite regulation, baseline GLP-1 signaling, and energy balance. It never predicts response to Wegovy or any medication; it is trait context, not a forecast. Compare with injectable Ozempic and injectable semaglutide.

Read this as education, not advice. The only GLP-1 compounds PlexusDx offers are semaglutide and tirzepatide, through its Weight Management Protocols; it does not handle dulaglutide, liraglutide, cagrilintide, or retatrutide. Retatrutide remains investigational and is not sold by PlexusDx. The Precision Peptide Genetic Test does not predict response to any specific medication. Consult a qualified healthcare provider before starting a peptide protocol.

Wegovy's place in the semaglutide lineup

Wegovy is best understood as the higher-dose, weight-management face of semaglutide, titrated up to 2.4 mg, while Ozempic carries the type 2 diabetes indication and tops out at 2 mg. Rybelsus, the daily oral tablet, is also labeled for type 2 diabetes, which means none of the oral options substitute for Wegovy in chronic weight management as of April 2026. Keeping those roles straight prevents a common assumption that any oral semaglutide is simply Wegovy in pill form, and it clarifies why the weekly injection is the only approved route for this particular product. Whether Wegovy or another option fits your situation is a decision for your prescribing provider, who weighs the FDA-approved indication on your prescription along with your history, concurrent medications, and the goals of therapy you have set.

Frequently Asked Questions

Is there an oral version of Wegovy?

Not as a Wegovy product. As of April 2026 there is no oral Wegovy. Rybelsus (oral semaglutide) is the only FDA-approved oral GLP-1 receptor agonist and is labeled for type 2 diabetes, not weight management. PlexusDx offers separate oral semaglutide and tirzepatide protocols through its Weight Management Protocols.

How is Wegovy different from Ozempic?

Both are once-weekly injectable semaglutide from Novo Nordisk, but Wegovy is labeled for chronic weight management and titrated up to 2.4 mg, while Ozempic is labeled for type 2 diabetes and goes up to 2 mg. Same molecule and route, different approved indication and dosing ceiling.

How does the injection compare with an oral tablet?

The Wegovy injection delivers predictable bioavailability with weekly dosing. Oral semaglutide relies on an absorption enhancer and strict fasting rules. Head-to-head weight-management efficacy data between the formats is limited, and oral semaglutide is approved for type 2 diabetes rather than weight management, so format choice is individual.

Does genetic testing predict my Wegovy results?

No. The Precision Peptide Genetic Test does not predict response to semaglutide or any compound or format. It reads pathway-level variants in FTO, GLP1R, MC4R, and TCF7L2 that relate to baseline GLP-1 and energy-balance biology — upstream context for a provider conversation, not a forecast of your outcome.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.